• Linezolid as a Mechanistic Benchmark in Antibacterial Assays

  2026-09-13

  Linezolid is more than a Gram-positive antibacterial control: it can anchor orthogonal assay design, target attribution, and resistance-focused experiments. This article connects its ribosomal mechanism with the MmpL3-directed spirocyclic POM study while clarifying what can—and cannot—be inferred across bacterial research domains.

• Oteseconazole (VT-1161) Candida Workflows

  2026-09-12

  Oteseconazole (VT-1161) combines potent fungal CYP51 inhibition with a practical research profile for Candida susceptibility, resistance, and biofilm studies. This workflow-focused guide covers stock preparation, MIC testing, comparative controls, and troubleshooting while defining where the compound should not be overinterpreted.

• Reparixin: CXCR1/2 Inhibitor Mechanism and Uses

  2026-09-12

  Reparixin is a non-competitive allosteric CXCR1/2 inhibitor used to investigate CXCL8-driven neutrophil signaling and migration. Product data support applications in inflammation research, while a 2026 study provides a mechanistic rationale for testing CXCR1 blockade in an MRSA extracellular-vesicle and oral cancer model.

• Topotecan for Ovarian Cancer: What the Review Shows

  2026-09-11

  This Cochrane review examined whether adding topotecan to carboplatin and paclitaxel improved outcomes for ovarian cancer. Its central finding was that the intensified regimen did not establish a meaningful overall-survival or progression advantage, while toxicity remained an important counterweight.

• Pyridostatin: From G4 Binding to Causal Assays

  2026-09-11

  Pyridostatin TFA is a structure-directed tool for probing G-quadruplex biology, but its most informative use depends on separating direct DNA effects from downstream stress phenotypes. This article presents a causal, compartment-aware assay framework connecting telomere biology research with emerging RNA G-quadruplex and TDP-43 findings.

• Measuring ROS to De-Risk Immuno-Oncology Translation

  2026-09-10

  A mechanistic and strategic guide to using intracellular superoxide measurements to connect redox biology with immuno-oncology decisions, while recognizing the strengths, limitations, and validation requirements of DHE-based workflows.

• Betaine Hydrochloride: A Smarter Assay Variable

  2026-09-10

  An evidence-aware framework for using Betaine hydrochloride to improve biochemical, cell-based, and inflammation-focused workflows without confusing assay utility with therapeutic evidence.

• Thioguanine Sensitivity in Relapsed T-ALL

  2026-09-09

  This study examined whether immunophenotypic lineage predicts in vitro drug resistance in childhood relapsed acute lymphoblastic leukaemia. Relapsed T-cell ALL was more sensitive to thiopurines, including thioguanine, but more resistant to selected DNA-damaging agents, providing a rationale for lineage-informed pharmacological studies without proving a clinical survival benefit.

• CF10–EdU Synergy Drives Telomere Attrition

  2026-09-09

  The reference study identifies a strong and mechanistically distinct interaction between the fluoropyrimidine polymer CF10 and 5-ethynyl-2′-deoxyuridine (EdU) in colorectal cancer cells. Its data connect enhanced EdU incorporation with DNA double-strand breaks, telomere attrition, cell-cycle disruption, and mitotic catastrophe, providing a framework for studying combined replication stress and telomere damage.

• HDAC Inhibition Reverses EBV-Driven NPC Plasticity

  2026-09-08

  The reference study identifies an LMP1–STAT5A–HDAC1/2–CEBPA pathway through which Epstein–Barr virus promotes dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma. Its xenograft evidence supports HDAC inhibition as a differentiation-oriented strategy for solid tumors, while also highlighting the need for disease-specific validation.

• GST-Driven Lambda-Cyhalothrin Resistance in Thrips

  2026-09-07

  This 2024 study identifies MuGSTs1-mediated antioxidant defense as a functional contributor to lambda-cyhalothrin resistance in Megalurothrips usitatus. By combining RT-qPCR, biochemical inhibition, oxidative-stress measurements, apoptosis markers, and sensitivity testing, the researchers connect GST activity with both redox protection and insecticide tolerance.

• Acetylcysteine (NAC) for Reliable Cell Assays

  2026-09-07

  Learn how Acetylcysteine (SKU A8356) can support controlled oxidative-stress, viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers concentration planning, assay compatibility, interpretation, and practical vendor-selection criteria.

• Reparixin for CXCR1/2 Signaling Workflows

  2026-09-05

  Reparixin provides a receptor-level way to test whether CXCL8–CXCR1/2 signaling drives neutrophil migration, inflammatory injury, or tumor-associated responses. This workflow connects MRSA extracellular-vesicle biology with practical chemotaxis, signaling, and in vivo study designs while clearly separating established evidence from experimental extensions.

• Gepotidacin Phase 2 Gonorrhea Trial: Key Findings

  2026-09-05

  A phase 2 randomized study evaluated whether a single oral dose of Gepotidacin, also known as GSK2140944, could eradicate uncomplicated urogenital Neisseria gonorrhoeae. The findings provide clinical proof of concept for a novel bacterial topoisomerase pathway and highlight both the potential and resistance-related limitations of this approach.

• AG-490: JAK2/STAT6 Assay Workflows

  2026-09-04

  Use AG-490 (Tyrphostin B42) as a mechanistic perturbation tool to test whether exosome-driven macrophage polarization depends on JAK2-linked signaling. This workflow combines phosphoprotein, transcriptional, uptake, and flow-cytometry readouts while accounting for AG-490’s EGFR, ErbB2, JAK3, and MAPK activity.

8642 records 5/577 page Previous Next 12345 下5页 Last page